fidaxomicin

Details

Generic Name:
fidaxomicin
Project Status:
Active
Therapeutic Area:
Clostridium difficile infection
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Dificid
Project Line:
Reimbursement Review
Project Number:
SF0847-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Fee Schedule:
N/A
Indications:
​Clostridium difficile infection.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open05-Feb-24
Request for Advice received29-Jan-24
Manufacturer informed of request for advice31-Jan-24
Manufacturer information or comments due14-Feb-24
Request for Advice initiated15-Feb-24
Call for patient/clinician input closed02-Apr-24
Draft CADTH review report(s) sent to sponsor16-Apr-24
Deadline for sponsors comments25-Apr-24
CADTH review report(s) and responses to comments provided to sponsor14-Jun-24
Expert committee meeting (initial)26-Jun-24
Draft recommendation posted for stakeholder feedback18-Jul-24
End of feedback period01-Aug-24